Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the effect of CC-90001, 200 mg and 400 mg, when orally administered (PO) once daily (QD), compared with placebo, on percent of predicted forced vital capacity (FVC) after 24 weeks of treatment in subjects with IPF.
Critère d'inclusion
- Idiopathic pulmonary fibrosis